Trial: 201904006

A multicentre, open-label, non-randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with epithelial tumours

Phase

I

Principal Investigator

Park, Haeseong

Disease Site

Breast; Cervix; Colon; Corpus Uteri; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Other Skin; Ovary; Pancreas; Rectum; Stomach; Urinary Bladder

Learn more about this study at: clinicaltrials.gov